Neuland Laboratories Limited — Updates, 15-05-2025: Press Release

Neuland Laboratories has announced a board meeting on the financial results for the quarter and half-year. Q4FY25 revenue fell 14% YoY to Rs.335.8 Cr, with EBITDA down 48% to Rs.58.2 Cr and PAT down 59% to Rs.27.7 Cr. FY25 revenue declined 4.7% to Rs.1,497 Cr, EBITDA fell 27.7% to Rs.343 Cr. Margin pressures stem from investments in peptides and customer expansion despite softer revenue. Growth is expected to pick up in FY26, supported by advancing molecules and custom manufacturing project wins.